1 Department of Thyroid and Breast Surgery, Qianfoshan Hospital, Shandong University , Jinan, Shandong, China .
2 Department of Thyroid and Breast Surgery, Binzhou Medical University Hospital , Binzhou, China .
Cancer Biother Radiopharm. 2017 Oct;32(8):282-287. doi: 10.1089/cbr.2017.2237.
Endoplasmic reticulum (ER) stress has been reported to be associated with metastasis in many malignant tumors. PKR-like ER kinase-phosphorylated eukaryotic translation initiation factor 2α (PERK-p-eIF2α) pathway is one of the three main signal pathways in ER stress, however, its mechanism in regulating breast cancer (BC) relapse or metastasis was still not completely understood. Besides, drug resistance was an important factor influencing the effect of tumor treatment and whether PERK-p-eIF2α pathway was involved in the drug resistance to BC treatment also needs to be explored. The authors conducted survival analysis of ER stress-related genes in the The Cancer Genome Atlas (TCGA) database to find the candidate molecule and found that eIF2α was significantly correlated with relapse-free survival in BC patients, especially in the triple-negative BC (TNBC) patients. Furthermore, BC cell lines were used to study the downstream target of PERK-p-eIF2α. In this study, p-eIF2α could negatively regulate the expression of programmed death ligand 1 (PDL1) and C-X-C motif chemokine ligand 5 (CXCL5), which were important ligands of the immune cells such as T cells and myeloid-derived suppressor cells in the tumor microenvironment. Besides, p-eIF2α expression in highly metastatic human TNBC cells after treatment of carboplatin was significantly decreased. The data indicated the possible novel immune-related mechanism of PERK-p-eIF2α in regulating TNBC metastasis and drug resistance of carboplatin in highly metastatic TNBC.
内质网(ER)应激已被报道与许多恶性肿瘤的转移有关。PKR 样 ER 激酶-磷酸化真核起始因子 2α(PERK-p-eIF2α)通路是 ER 应激的三条主要信号通路之一,但其在调节乳腺癌(BC)复发或转移的机制尚不完全清楚。此外,耐药性是影响肿瘤治疗效果的重要因素,PERK-p-eIF2α 通路是否参与 BC 治疗的耐药性也需要进一步探索。作者通过对癌症基因组图谱(TCGA)数据库中 ER 应激相关基因进行生存分析,寻找候选分子,发现 eIF2α 与 BC 患者的无复发生存率显著相关,尤其是在三阴性 BC(TNBC)患者中。此外,作者还使用 BC 细胞系研究了 PERK-p-eIF2α 的下游靶点。在这项研究中,p-eIF2α 可以负调控程序性死亡配体 1(PDL1)和 C-X-C 基序趋化因子配体 5(CXCL5)的表达,它们是肿瘤微环境中 T 细胞和髓源性抑制细胞等免疫细胞的重要配体。此外,经卡铂处理后,高转移性人 TNBC 细胞中的 p-eIF2α 表达明显降低。这些数据表明 PERK-p-eIF2α 可能通过调节 TNBC 转移和高转移性 TNBC 对卡铂的耐药性具有新的免疫相关机制。